Katsuya Otori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katsuya Otori has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Kazuo Yago
-year pharmacy education, Kitasato University Hospital
2 shared publicationsKiyoshi Shibuya
Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, Tokyo, Japan
2 shared publications- Manahito Aoki
Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, Tokyo, Japan
2 shared publications - Masahiro Kobayashi
Laboratory of Clinical Pharmacokinetics, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, Sagamihara, Japan
2 shared publications - Tatsuya Okuwaki
Department of Pharmacy, Kitasato University Hospital, Tokyo, Japan
2 shared publications Atsushi Shibazaki
Department of Pharmacy, Kitasato University Medical Center
1 shared publication
Latest Publications
- 28 August 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 60 (1) , 182-189
Descriptions of Abnormal Kidney Function in Contraindications: A Cross-Sectional Analysis of Japanese Prescription Drug Labeling Under the New Format
Background In Japan, prescription drug labeling has transitioned to a new structured format aimed at improving clarity and consistency, with full implementation in March 2024. Abnormal kidney function, a critical determinant of drug safety, necessitates clear and consistent contraindication labeling. However, current labeling practices have not been comprehensively evaluated. Objective To systematically assess how kidney-related contraindications are described in Japanese package inserts under the new labeling format. Methods We reviewed all electronically available prescription drug package inserts as of October 1, 2024. Using 20 kidney-related keywords, we extracted and analyzed statements in Sect. 2 (“Contraindications”), categorizing them into four domains: type of impairment, severity, disease progression, and quantitative criteria. Additionally, a network diagram of co-occurring terms was developed to illustrate the consistency and diversity of terminology. Results A total of 233 kidney-related contraindication statements were identified across 182 pharmaceutical ingredients. Type of impairment was mentioned in 81.5%, severity in 54.9%, and quantitative criteria in 38.2%. However, the terminology and threshold values used were inconsistent. Terms such as “severe abnormal kidney function” were used without standardized definitions, and quantitative parameters (e.g., creatinine clearance, estimated glomerular filtration rate) varied across products. Conclusion Despite regulatory efforts to enhance labeling structure, kidney-related contraindication descriptions in Japan remain variable and lack standardization. These inconsistencies may hinder safe prescribing practices and the integration of labeling into clinical decision support systems. Adoption of internationally harmonized terminology, such as KDIGO staging, and clearer regulatory guidance may improve the clinical utility of drug labeling.
- 28 August 2025
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 60 (1) , 182-189
Descriptions of Abnormal Kidney Function in Contraindications: A Cross-Sectional Analysis of Japanese Prescription Drug Labeling Under the New Format
Background In Japan, prescription drug labeling has transitioned to a new structured format aimed at improving clarity and consistency, with full implementation in March 2024. Abnormal kidney function, a critical determinant of drug safety, necessitates clear and consistent contraindication labeling. However, current labeling practices have not been comprehensively evaluated. Objective To systematically assess how kidney-related contraindications are described in Japanese package inserts under the new labeling format. Methods We reviewed all electronically available prescription drug package inserts as of October 1, 2024. Using 20 kidney-related keywords, we extracted and analyzed statements in Sect. 2 (“Contraindications”), categorizing them into four domains: type of impairment, severity, disease progression, and quantitative criteria. Additionally, a network diagram of co-occurring terms was developed to illustrate the consistency and diversity of terminology. Results A total of 233 kidney-related contraindication statements were identified across 182 pharmaceutical ingredients. Type of impairment was mentioned in 81.5%, severity in 54.9%, and quantitative criteria in 38.2%. However, the terminology and threshold values used were inconsistent. Terms such as “severe abnormal kidney function” were used without standardized definitions, and quantitative parameters (e.g., creatinine clearance, estimated glomerular filtration rate) varied across products. Conclusion Despite regulatory efforts to enhance labeling structure, kidney-related contraindication descriptions in Japan remain variable and lack standardization. These inconsistencies may hinder safe prescribing practices and the integration of labeling into clinical decision support systems. Adoption of internationally harmonized terminology, such as KDIGO staging, and clearer regulatory guidance may improve the clinical utility of drug labeling.
- 9 December 2024
- Published by Springer Nature in International Urology and Nephrology
- p. 1-8
Vancomycin-associated acute kidney injury in underweight patients: a propensity score matching analysis
Purpose To investigate the effect of being underweight on the incidence of vancomycin-associated acute kidney injury (AKI) using propensity score matching analysis. Methods This study is a retrospective analysis of patients who received vancomycin and had their serum concentration measured at Kitasato University Hospital between January 1, 2016 and December 31, 2020. Patients were divided into underweight and non-underweight groups based on body mass index (BMI), and propensity score matching analysis was used to evaluate whether underweight affected the incidence of acute kidney injury. Results 480 patients met the selection criteria, and 111 patients from each group (BMI < 18.5 and BMI ≥ 18.5) were successfully matched using propensity score matching. After matching, there were no differences in non-physical characteristics between the two groups. The incidence of AKI was 23.4% (26 of 111) in the BMI < 18.5 group and 37.8% (42 of 111) in the BMI ≥ 18.5 group, with the BMI < 18.5 group having a significantly lower incidence. The odds ratio was 0.503 [95% CI 0.281–0.900]. Conclusion This study showed that underweight patients (BMI < 18.5) had a significantly lower incidence of vancomycin-associated AKI compared to those with BMI ≥ 18.5. As there have been no previous reports on the association between underweight and vancomycin-associated AKI, this study provides novel insights.
- 9 December 2024
- Published by Springer Nature in International Urology and Nephrology
- p. 1-8
Vancomycin-associated acute kidney injury in underweight patients: a propensity score matching analysis
Purpose To investigate the effect of being underweight on the incidence of vancomycin-associated acute kidney injury (AKI) using propensity score matching analysis. Methods This study is a retrospective analysis of patients who received vancomycin and had their serum concentration measured at Kitasato University Hospital between January 1, 2016 and December 31, 2020. Patients were divided into underweight and non-underweight groups based on body mass index (BMI), and propensity score matching analysis was used to evaluate whether underweight affected the incidence of acute kidney injury. Results 480 patients met the selection criteria, and 111 patients from each group (BMI < 18.5 and BMI ≥ 18.5) were successfully matched using propensity score matching. After matching, there were no differences in non-physical characteristics between the two groups. The incidence of AKI was 23.4% (26 of 111) in the BMI < 18.5 group and 37.8% (42 of 111) in the BMI ≥ 18.5 group, with the BMI < 18.5 group having a significantly lower incidence. The odds ratio was 0.503 [95% CI 0.281–0.900]. Conclusion This study showed that underweight patients (BMI < 18.5) had a significantly lower incidence of vancomycin-associated AKI compared to those with BMI ≥ 18.5. As there have been no previous reports on the association between underweight and vancomycin-associated AKI, this study provides novel insights.
- 1 June 2021
- Published by American Diabetes Association in Diabetes
- Vol. 70 (Supplement)
1007-P: Risk Factor for COVID-19 Infection-Related Hospitalization in Patients with Type 2 Diabetes
Objective: Coronavirus disease (COVID-19) in 2019 is highly prevalent among patients with type 2 diabetes (T2D). Several factors, such as the older and obesity have been reported to be risks of COVID-19 infection, but little is known about the clinical factors limited to patients with T2D. Here, we aimed to identify clinical factors linked to hospitalization with COVID-19 infection in T2D. Research Design and Methods: We used data from Electronic Medical Record (EHR) registered in the Healthjump database provided by the COVID-19 Research Database consortium. Primary outcomes were to determine clinical factors linked to COVID-19 infection-associated hospitalization. Results: Of 4,445 T2D patients with COVID-19, hospitalization occurred in 228 (5.1%). The risk of Covid-19 infection-related hospitalization was higher with ≥65years old (hazard ratio [HR] 1.45; 95% confidence interval [CI], 1.30-1.63), high in patients with a body-mass index (BMI) ≥30 kg/m2 (HR 1.59; 95% CI, 1.10-2.31), and Blacks than in Caucasians (HR 1.39; 95% CI, 1.04-1.85). The risk was lower in Metformin users (HR 0.56; 95% CI, 0.34-1394) and SGLT2inhibitors users (HR 0.45; 95% CI, 0.22-0.91). Asians tended to be at increased risk, but there was no significant difference due to the small number of cases (HR 1.88; 95% CI, 0.59-5.96). Conclusions: We revealed that the risk of hospitalization may be higher with older, obesity and blacks. Furthermore, we discovered a low risk of hospitalization in patients with treated SGLT2 inhibitors and/or metformin. These findings can help inform patient-centered care decision making for people with T2D at risk for COVID-19. Disclosure: T. Horii: None. W. Ando: None. K. Otori: None. K. Atsuda: None.
- 1 June 2021
- Published by American Diabetes Association in Diabetes
- Vol. 70 (Supplement)
1007-P: Risk Factor for COVID-19 Infection-Related Hospitalization in Patients with Type 2 Diabetes
Objective: Coronavirus disease (COVID-19) in 2019 is highly prevalent among patients with type 2 diabetes (T2D). Several factors, such as the older and obesity have been reported to be risks of COVID-19 infection, but little is known about the clinical factors limited to patients with T2D. Here, we aimed to identify clinical factors linked to hospitalization with COVID-19 infection in T2D. Research Design and Methods: We used data from Electronic Medical Record (EHR) registered in the Healthjump database provided by the COVID-19 Research Database consortium. Primary outcomes were to determine clinical factors linked to COVID-19 infection-associated hospitalization. Results: Of 4,445 T2D patients with COVID-19, hospitalization occurred in 228 (5.1%). The risk of Covid-19 infection-related hospitalization was higher with ≥65years old (hazard ratio [HR] 1.45; 95% confidence interval [CI], 1.30-1.63), high in patients with a body-mass index (BMI) ≥30 kg/m2 (HR 1.59; 95% CI, 1.10-2.31), and Blacks than in Caucasians (HR 1.39; 95% CI, 1.04-1.85). The risk was lower in Metformin users (HR 0.56; 95% CI, 0.34-1394) and SGLT2inhibitors users (HR 0.45; 95% CI, 0.22-0.91). Asians tended to be at increased risk, but there was no significant difference due to the small number of cases (HR 1.88; 95% CI, 0.59-5.96). Conclusions: We revealed that the risk of hospitalization may be higher with older, obesity and blacks. Furthermore, we discovered a low risk of hospitalization in patients with treated SGLT2 inhibitors and/or metformin. These findings can help inform patient-centered care decision making for people with T2D at risk for COVID-19. Disclosure: T. Horii: None. W. Ando: None. K. Otori: None. K. Atsuda: None.
- Open Access
- 4 May 2021
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 7 (1) , 1-8
Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube
Background: In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube. However, there is no report on the changes occurring when suspensions of these two drugs are combined, including the effects or potential decrease in dose following tube administration. Thus, the purpose of our study was to investigate the (i) changes caused by mixing clopidogrel bisulfate (ion form) and MgO tablets and (ii) effects on the administered clopidogrel dose after passing through a feeding tube. Methods: The molecular structure of clopidogrel generated in a mixture of clopidogrel bisulfate and a basic compound, such as sodium bicarbonate or MgO tablet, was determined by 1H-NMR after extraction and purification. The suspension of clopidogrel bisulfate tablet alone and the mixed suspension of clopidogrel bisulfate tablet and MgO tablet were passed through a feeding tube. We compared the yield of the molecular form of clopidogrel from each passed fraction. Results: The substance obtained from the mixture of clopidogrel bisulfate tablet and sodium bicarbonate or MgO tablet was identified as the molecular form of clopidogrel, and chemical degradation did not occur under these conditions. In the tube passage test, the yield of clopidogrel (molecular form) from the mixture of clopidogrel bisulfate and MgO tablets was lower than that from the suspension of clopidogrel bisulfate tablet alone. Conclusions: The mixture of clopidogrel bisulfate and MgO tablets caused a considerable reduction in the administered dose passed through the feeding tube. Therefore, it is recommended to administer the suspensions of clopidogrel bisulfate and MgO tablets separately for safe and effective pharmacotherapy.
- 4 May 2021
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 7 (1) , 1-8
Open AccessMixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube
Background: In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube. However, there is no report on the changes occurring when suspensions of these two drugs are combined, including the effects or potential decrease in dose following tube administration. Thus, the purpose of our study was to investigate the (i) changes caused by mixing clopidogrel bisulfate (ion form) and MgO tablets and (ii) effects on the administered clopidogrel dose after passing through a feeding tube. Methods: The molecular structure of clopidogrel generated in a mixture of clopidogrel bisulfate and a basic compound, such as sodium bicarbonate or MgO tablet, was determined by 1H-NMR after extraction and purification. The suspension of clopidogrel bisulfate tablet alone and the mixed suspension of clopidogrel bisulfate tablet and MgO tablet were passed through a feeding tube. We compared the yield of the molecular form of clopidogrel from each passed fraction. Results: The substance obtained from the mixture of clopidogrel bisulfate tablet and sodium bicarbonate or MgO tablet was identified as the molecular form of clopidogrel, and chemical degradation did not occur under these conditions. In the tube passage test, the yield of clopidogrel (molecular form) from the mixture of clopidogrel bisulfate and MgO tablets was lower than that from the suspension of clopidogrel bisulfate tablet alone. Conclusions: The mixture of clopidogrel bisulfate and MgO tablets caused a considerable reduction in the administered dose passed through the feeding tube. Therefore, it is recommended to administer the suspensions of clopidogrel bisulfate and MgO tablets separately for safe and effective pharmacotherapy.
- Open Access
- 1 January 2021
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 141 (1) , 125-133
Safe Handling Method for Splitting Azathioprine Tablets
The immunosuppressant azathioprine (AZA) is classified as a hazardous drug. AZA contamination during tablet-splitting increases exposure risk. However, there is no study on contamination and exposure during AZA tablet splitting and dispensing. AZA tablet splitting and dispensing methods were classified based on whether tweezers are used during splitting and packaging. In Dispensing Method (1), no tweezers were used in either step. In Dispensing Method (2), no tweezers were used during tablet splitting, but were used during packaging. In Dispensing Method (3), tweezers were used in both steps. After AZA half-tablet split-dispensing, we quantified the adherent AZA removed from the tools, packaging machines, and dispensing counters by three consecutive wipings with water-dampened polypropylene cloths. A large amount of AZA adhered to the gloves used in Dispensing Methods (1) and (2), wherein tablets were placed with gloved hands, compared with Dispensing Method (3), wherein tablets were held with tweezers. Thus, the gloves must be replaced before touching the packaging paper during the final step. After three consecutive wipings, AZA was not detected at most of the sites in the third round. Thus, we recommend that (1) AZA tablet splitting should be performed while wearing gloves, (2) the gloves should be changed before packaging the half tablets, and (3) the tools, packaging machines, and dispensing counters should be wiped twice or thrice with a water-dampened cloth after dispensing.
- 1 January 2021
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 141 (1) , 125-133
Open AccessSafe Handling Method for Splitting Azathioprine Tablets
The immunosuppressant azathioprine (AZA) is classified as a hazardous drug. AZA contamination during tablet-splitting increases exposure risk. However, there is no study on contamination and exposure during AZA tablet splitting and dispensing. AZA tablet splitting and dispensing methods were classified based on whether tweezers are used during splitting and packaging. In Dispensing Method (1), no tweezers were used in either step. In Dispensing Method (2), no tweezers were used during tablet splitting, but were used during packaging. In Dispensing Method (3), tweezers were used in both steps. After AZA half-tablet split-dispensing, we quantified the adherent AZA removed from the tools, packaging machines, and dispensing counters by three consecutive wipings with water-dampened polypropylene cloths. A large amount of AZA adhered to the gloves used in Dispensing Methods (1) and (2), wherein tablets were placed with gloved hands, compared with Dispensing Method (3), wherein tablets were held with tweezers. Thus, the gloves must be replaced before touching the packaging paper during the final step. After three consecutive wipings, AZA was not detected at most of the sites in the third round. Thus, we recommend that (1) AZA tablet splitting should be performed while wearing gloves, (2) the gloves should be changed before packaging the half tablets, and (3) the tools, packaging machines, and dispensing counters should be wiped twice or thrice with a water-dampened cloth after dispensing.
- Open Access
- 16 March 2020
- Published by Springer Nature in BMC Research Notes
- Vol. 13 (1) , 1-5
Handling and packaging of medical bags at acute disaster sites under high-temperature conditions
After the large-scale earthquake in 2011, the disaster medical assistance team (DMAT) was made responsible for medical activities during the hyperacute phase of a disaster or accident in Japan. The medicines to be administered at the disaster sites, packaged in medical bags, may be affected by the temperatures there. This study aimed at establishing a method to handle drug bags in high-temperature situations by determining the temperature changes in medical bags subject to high temperatures and examining the effect of opening the bag and using heat-insulating material (HIM) and coolants. Closed and semi-opened bags limited the temperature increase in the central part of the bag at both 35 and 40 °C to a greater extent than opened bags. When coolant and HIM were used in closed and semi-opened bags, the internal temperatures were significantly lower than in the opened state at 40 °C. In high-temperature disaster sites, medical bags should be maintained in a semi-opened or closed state using a HIM and coolant.
- 16 March 2020
- Published by Springer Nature in BMC Research Notes
- Vol. 13 (1) , 1-5
Open AccessHandling and packaging of medical bags at acute disaster sites under high-temperature conditions
After the large-scale earthquake in 2011, the disaster medical assistance team (DMAT) was made responsible for medical activities during the hyperacute phase of a disaster or accident in Japan. The medicines to be administered at the disaster sites, packaged in medical bags, may be affected by the temperatures there. This study aimed at establishing a method to handle drug bags in high-temperature situations by determining the temperature changes in medical bags subject to high temperatures and examining the effect of opening the bag and using heat-insulating material (HIM) and coolants. Closed and semi-opened bags limited the temperature increase in the central part of the bag at both 35 and 40 °C to a greater extent than opened bags. When coolant and HIM were used in closed and semi-opened bags, the internal temperatures were significantly lower than in the opened state at 40 °C. In high-temperature disaster sites, medical bags should be maintained in a semi-opened or closed state using a HIM and coolant.
- Open Access
- 1 January 2012
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 38 (11) , 694-701
The Impact of Faculty Functioning as Institutional Pharmacists on Pharmacy Practice in a Hospital
- 1 January 2012
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Vol. 38 (11) , 694-701
Open AccessThe Impact of Faculty Functioning as Institutional Pharmacists on Pharmacy Practice in a Hospital
- Open Access
- 1 January 1996
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Japanese Journal of Hospital Pharmacy
- Vol. 22 (4) , 359-363
Adsorption of rhG-CSF to Various Intravenous Filters.
- 1 January 1996
- Published by Japanese Society of Pharmaceutical Health Care and Sciences in Japanese Journal of Hospital Pharmacy
- Vol. 22 (4) , 359-363
Open AccessAdsorption of rhG-CSF to Various Intravenous Filters.